drugset / Trial / NCT00223041

Cranoc Lipid Study in Renal Transplantation

NCT00223041

Phase 2/3 Terminated 200 enrolled University Hospital Schleswig-Holstein
RandomizedParallel-groupOpen-labelPrevention

Summary

Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (\<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.

Timeline

Start
2003-04
Primary completion
2009-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluvastatin Other / unclassified 80 mg

Indications

No indication recorded.